Intra-Cellular Therapies Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: New York NY United States (2002)

Organization Overview

First Clinical Trial
2011
NCT01499563
First Marketed Drug
2019
lumateperone (Caplyta)
First NDA Approval
2019
lumateperone (Caplyta)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

INTRA-CELLULAR | Intra-Cellular Therapies Inc | Intra-Cellular Therapies, Inc. | INTRA-CELLULAR THERAPIES INC | Intra-Cellular Therapies, Inc. (ITI)

Active Ingredients

Marketed Drugs (1)

lumateperone (Caplyta) (2019 NDA)

Drugs in Phase 3 Trials (3)

iti-007 (9 trials)

lumateperone (Caplyta) (10 trials)

risperidone (risperdal) (2 trials)

Drugs in Phase 2 Trials (1)

iti-214 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Bipolar Disorder (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Heart Failure (Phase 2)

Heart Failure, Systolic (Phase 2)

Parkinson Disease (Phase 2)

Psychomotor Agitation (Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 4